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Abstract: Endoplasmic reticulum (ER) stress is involved in the pathogenesis of several diseases 
including Alzheimer disease and Parkinson disease. Many recent studies have shown that ER 
stress is related to the pathogenesis of diabetes mellitus, and with the death of pancreatic β-cells, 
insulin resistance, and the death of the vascular cells in the retina. Diabetic retinopathy is a major 
complication of diabetes and results in death of both neural and vascular cells. Because the 
death of the neurons directly affects visual function, the precise mechanism causing the death 
of neurons in early diabetic retinopathy must be determined. The ideal therapy for preventing 
the onset and the progression of diabetic retinopathy would be to treat the factors involved with 
both the vascular and neuronal abnormalities in diabetic retinopathy. In this review, we present 
evidence that ER stress is involved in the death of both retinal neurons and vascular cells in 
diabetic eyes, and thus reducing or blocking ER stress may be a potential therapy for preventing 
the onset and the progression of diabetic retinopathy.
Keywords: endoplasmic reticulum stress, diabetic retinopathy, vascular cell death, neuronal 
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Introduction
Diabetic retinopathy is a major complication in patients with diabetes and it can lead to 
severe visual decrease in a high percentage of diabetic patients (Oshitari 2006; Oshitari 
and Roy 2007). Although the precise mechanism(s) for the onset and progression 
of diabetic retinopathy has still not been determined, recent studies have indicated 
that neuronal and vascular abnormalities are associated with the pathogenesis of 
early diabetic retinopathy (Barber et al 1998; Takano et al 1999; Asnaghi et al 2003; 
Martin et al 2004; Oshitari et al 2005). The neuronal abnormalities in the early stage 
of diabetic retinopathy are difﬁ  cult to observe and evaluate by routine clinical tests, 
but ophthalmologists should consider neuronal abnormalities, including the death of 
retinal ganglion cell (RGCs), when evaluating eyes with diabetic retinopathy. This is 
important because the death of retinal neurons is irreversible and directly affects the 
visual function (Oshitari 2006; Oshitari and Roy 2007).
The endoplasmic reticulum (ER) is a critical intracellular organelle, which has 
several vital functions such as protein synthesis (Chevet et al 2001), protein transport 
(Palade 1975), and acts as a reservoir of Ca2+ (Nielsen and Podolsky 1972). The accu-
mulation of unfolded proteins or an upset in the Ca2+ homeostasis in the ER will activate 
the ER stress response, eg, the unfolded protein response (UPR) and the ER overload 
response (Rao et al 2004; Lindholm et al 2006). Most importantly, ER stress activates 
several cell death pathways including the caspase-12-dependent pathway (Nakagawa 
et al 2000), apoptosis signal-regulating kinase 1 (ASK1) – c-Jun N-terminal kinase 
(JNK) pathway (Nishitoh et al 2002) and the PKR-like endoplasmic reticulum kinase 
(PERK) – C/ERB homologous protein (CHOP) pathway (Ma et al 2002) (Figure 1).Vascular Health and Risk Management 2008:4(1) 116
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The results of recent studies have shown that ER 
stress-mediated cell death is associated with the death of pan-
creatic β-cells in patients with diabetes (Oyadomari et al 2001, 
2002; Laybutt et al 2007). In addition, a recent study reported 
that the ER stress-induced apoptosis is related to changes in 
the glucose concentration and results in the death of pericytes 
(Ikesugi et al 2006). Roybal and colleagues (2004) suggested 
that the ER stress-mediated activating transcriptional factor 
4 (ATF4) activation was associated with an over-expression 
of vascular endothelial growth factor (VEGF). In addition, 
recent studies indicate that ER stress-induced apoptosis is 
involved in the death of neurons in the brain and retina under 
different physiological conditions (Guo et al 1997; Tobisawa 
et al 2003; Imai and Takahashi 2004; Larner et al 2004; Tajiri 
et al 2004; Wootz et al 2004; Hayashi et al 2005; Awai et al 
2006; Shimazawa et al 2007).
One therapeutic strategy that might be used to prevent 
the development and progression of type 2 diabetes is the 
inhibition of ER stress. This would then block the ER 
stress-induced pancreatic β-cell death, and may also prevent 
the onset and progression of diabetic retinopathy. We shall 
discuss the possible role of ER stress in the pathogenesis 
of diabetic retinopathy and describe potential therapeutic 
strategies to block the development and the progression of 
diabetic retinopathy.
ER stress-mediated pancreatic 
β-cell death in diabetes
The ER is involved in the maintenance of cellular homeostasis 
by inducing the UPR. The UPR of mammals is mediated by at 
least three types of ER transmembrane proteins; IRE1 (protein 
kinase and site-specific endoribonuclease) (Tirasophon 
et al 1998; Wang et al 1998), PERK (Harding et al 2000), 
and ATF6 (Ye et al 2000). Under diabetic conditions, the 
pancreatic β-cells are continuously exposed to oxidative 
stress, eg, exposure to reactive oxygen species (ROS; 
Kaneto et al 2005) and to nitrous oxide (NO; Oyadomari 
et al 2001). The ER is highly developed in pancreatic β-cells 
Figure 1 Hypothesized scheme of the ER stress-mediated cell death pathways. At least, three major cell death pathways are associated with ER stress-induced cell death. 
Abbreviations: ER, endoplasmic reticulum; TRAF2, tumor necrosis factor receptor-associated factor 2;  ASK1, apoptosis signal-regulating kinase 1; SEK1, SAPK/ERK kinase 1; MKK7, 
mitogen-activated protein kinase kinase 7; JNK, c-Jun N-terminal kinase;   ATF4, activating transcription factor 4; PERK, PKR-like endoplasmic reticulum kinase; elF2α, a subunit 
of translation eukaryotic initiation factor 2; CHOP, C/ERB homologous protein.Vascular Health and Risk Management 2008:4(1) 117
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because of the continuous insulin secretion. Thus, it seems 
that even under physiological conditions, a potential ER 
stress is present because there are many unfolded proteins 
and premature proteins in the ER of pancreatic β-cells 
(Harding et al 2001; Weir et al 2001). These unfolded and 
premature proteins can easily become targets of ROS and 
NO (Oyadomari et al 2001; Kaneto et al 2005). Once the ER 
stress is increased in pancreatic β-cells, the JNK- and CHOP-
mediated cell death pathways are activated (Oyadomari et al 
2001, 2002; Kaneto et al 2005). The activation of the JNK 
pathway under diabetic stress is known to induce the serine 
phosphorylation of insulin receptor substance 1, which in 
turn leads to insulin resistance (Özcan et al 2004). When 
the number of pancreatic β-cell is decreased, ER stress is 
increased in the remaining pancreatic β-cells to compensate 
for the reduced insulin secretion leading to pancreatic β-cell 
dysfunction (Weir et al 2001; Poitout et al 2002). Thus, ER 
stress-mediated pancreatic β-cell death is critical and a key 
alteration for the pathogenesis of type 2 diabetes.
ER stress involved in vascular 
abnormalities in eyes with diabetic 
retinopathy
The loss of pericytes from the microvessels in diabetic retinas 
is one of the characteristic pathological changes in the early 
stage of diabetic retinopathy. The results of a recent study 
indicated that the UPR, activated by ER stress, is induced in 
retinal pericytes by the changes in the glucose concentration 
(Ikesugi et al 2006). Thus, ER stress-mediated cell death is 
the common pathology in the death of pancreatic β-cells and 
pericytes in diabetes.
VEGF plays important roles in the pathogenesis of dia-
betic retinopathy (Shweiki et al 1992; Amin et al 1997; Lu 
et al 1998; Ishida et al 2000; Qaum et al 2001; El-Remessy 
et al 2003). The expression of VEGF is increased in dia-
betic retinas by the high-glucose, ischemia, and hypoxia, 
and this leads to the development of neovascularization 
and/or increased vascular permeability (Shweiki et al 1992; 
Amin et al 1997; Lu et al 1998; Ishida et al 2000; Qaum 
et al 2001; El-Remessy et al 2003). Abcouwer et al showed 
that the glutamine deprivation-induced ER stress is associ-
ated with an up-regulation of VEGF expression in human 
retinal pigment epithelial cells (Abcouwer et al 2002). 
Roybal and colleagues (2004) suggested that the homocys-
teine-induced ER stress is related to the over-expression 
of VEGF under the control of ATF4. Hyperglycemia has 
been suggested to increase the intracellular homocysteine 
levels in the retinal pigment epithelium cells. Thus, there 
is good evidence that the diabetic stress-induced ER stress 
is involved in vascular abnormalities such as pericyte loss 
and neovascularization.
ER-stress-mediated neuronal 
cell death
Recent studies have shown that RGCs die at the early stage 
of diabetes (Barber et al 1998; Asnaghi et al 2003; Oshitari 
and Roy 2005). The neuronal abnormalities, such as RGC 
death, are irreversible and may precede the vascular abnor-
malities including the increased vascular permeability in 
diabetic retinas. This is observed even in retinas with a clini-
cal diagnosis of non-diabetic retinopathy, however neuronal 
abnormalities, such as the reduction of retinal nerve ﬁ  ber 
thickness, can be detected by optical coherence tomography 
even at this stage (Sugimoto et al 2005).
Guo and colleagues (1997) suggest that an upset of the Ca2+ 
homeostasis in the ER caused by mutations in presenilin-1 is 
associated with the neuronal cell death in Alzheimer’s disease. 
Recently, many studies have reported that the ER stress-
mediated neuronal cell death is related to the pathogenesis of 
various neuronal diseases in the brain and retina, eg, polyglu-
tamine diseases (Nishito et al 2002), Parkinson’s disease (Imai 
and Takahashi 2004), amyotrophic lateral sclerosis (Tobisawa 
et al 2003; Wootz et al 2004), acute brain disorders (Larner 
et al 2004; Tajiri et al 2004; Hayashi et al 2005), and retinal 
ischemia (Awai et al 2006; Shimazawa et al 2007).
Other studies have shown that the PERK-CHOP pathway, 
one of the ER stress-mediated pathways that is induced in 
ischemic retinas, is related to neuronal cell death (Awai et al 
2006; Shimazawa et al 2007). It is well-known that under 
ischemic stress, an increase of intracellular Ca2+ level disturbs 
the ER Ca2+ homeostasis which in turn leads to ER stress-
induced neuronal degeneration (Verkhratsky and Toescu 
2003). Unfolded proteins that accumulate in the ER in ischemic 
retinas become targets of ROS and NO. Thus, it seems 
reasonable that in ischemic retinas, the ER stress-mediated cell 
death pathways are related to the neuronal degeneration.
We have examined the IRE1-JNK pathway to determine 
if it is associated with the neuronal death in ischemic retinas 
using the ischemia-reperfusion injury model (unpublished 
data). Our results suggested that the expressions of IRE1α 
and tumor necrosis factor receptor-associated factor 2 
(TRAF2) were signiﬁ  cantly increased in the ischemic retinas 
compared to that in control retinas. In addition, we found 
that the expression of ASK1, SAPK/ERK kinase 1 (SEK1), 
and JNK were expressed in the same degenerating neurons Vascular Health and Risk Management 2008:4(1) 118
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of ischemic retinas (unpublished data). Thus, not only the 
PERK-CHOP pathway but also the IRE1-JNK pathway is 
associated with neuronal death in ischemic retinas.
The exact mechanism leading to the death of RGCs has 
not been conclusively determined especially at the early 
stage of diabetic retinopathy. One possible link between 
vascular abnormalities and neuronal abnormalities may be 
the changes in the glial cells at the early stage of diabetic reti-
nopathy (Figure 2). Glial processes make contact with both 
the blood vessels and neurons, and form the blood-retinal 
barrier (Kim et al 2006) (Figure 2). Glial cells can maintain 
the blood-retinal barrier by expressing VEGF, and there are 
many studies that have shown interactions between glial cells 
and neuronal cells in the retina (Fruttiger et al 1996; Rauen 
et al 1999; Harada et al 2000). During the onset and the pro-
gression of diabetic retinopathy, Müller cells are changed, 
eg, up-regulation of glial ﬁ  brillary acidic protein (GFAP) and 
accumulation of gamma-aminobutyric acid (Ishikawa et al 
1996; Lieth et al 1998; Barber et al 2000; Rungger-Brändle 
et al 2000). Pannicke and colleagues (2006) suggested 
that glial abnormalities, eg, swelling of the cell body, may 
lead to the retinal edema detected in diabetic retinas. Thus, 
neuro-glial interactions may be involved at the onset and the 
progression of diabetic retinopathy, and glial changes may 
be related to both neuronal and vascular abnormalities at the 
early stage of diabetic retinopathy (Figure 2).
The glutamate levels are known to be elevated in the 
vitreous of diabetic patients (Ambati et al 1997), which 
could lead to neuronal cell death. Because an over-stimula-
tion of neurons by glutamate upsets the Ca2+ homeostasis in 
the ER, ER stress may be present in degenerating neurons 
under diabetic stress.
Because there is very little evidence of a direct association 
of ER stress and the pathogenesis of diabetic retinopathy, 
ER stress may be an epiphenomenon and/or only one of the 
players, perhaps with a minor role, in the development of 
diabetic retinopathy. Thus, although ER-stress-related factors 
may be promising targets for the prevention and the progres-
sion of diabetic retinopathy, additional studies are needed to 
determine the relationship between ER stress and neuronal 
cell death in diabetic retinas.
Potential therapeutic strategies 
for diabetic retinopathy
An epidemiological study performed by the Japanese Minis-
try of Welfare in 2005 showed that diabetic retinopathy was 
the second most common eye disease to cause blindness in 
the Japanese. Over 3,000 patients with diabetic retinopathy 
Figure 2 Hypothesized scheme of the pathogenesis of early diabetic retinopathy. The characteristic changes of early diabetic retinas may be glial changes, which in turn 
leads to vascular and neuronal abnormalities such as increased vascular permeability or neuronal cell death. The ideal therapies for diabetic retinopathy may be the improve-
ment of both vascular and neuronal abnormalities. 
Abbreviations: GFAP, glial ﬁ  brillary acidic protein; GABA, gamma-aminobutyric acid.Vascular Health and Risk Management 2008:4(1) 119
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lose their vision each year in Japan. This indicates that the 
current management and therapies for diabetic retinopathy 
are not sufﬁ  cient to prevent the progression to blindness in 
patients with diabetic retinopathy. To reduce the number of 
patients who lose their vision from diabetic retinopathy, new 
therapeutic strategies must be established to prevent the onset 
and the progression of the diabetic retinopathy.
At present, the standard treatments for diabetic retinopathy 
include: control of the blood glucose levels and the blood 
pressure (Klein et al 1995; Diabetes Control and Complica-
tions Trial Research Group 1995a, 1995b; UK Prospective 
Diabetes Study (UKPDS) Group 1998; Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions 
and Complications Research Group 2000; Writing Team for 
the Diabetes Control and Complications Trial/Epidemiol-
ogy of Diabetes Interventions and Complications Research 
Group 2002; Matthews et al 2004), focal laser photocoagula-
tion (Early Treatment Diabetic Retinopathy Study Research 
Group 1985, 1987, 1991a), pan-retinal laser photocoagulation 
(Diabetic Retinopathy Study Research Group 1978, 1981), 
and early vitrectomy (Diabetic Retinopathy Vitrectomy Study 
Research Group 1985a, 1985b, 1988a, 1988b, 1990). Although 
the diabetic retinopathy continues to progress in some patients 
in spite of good control of blood glucose and blood pressure, a 
tight control of blood glucose levels and blood pressure is the 
ﬁ  rst choice for the treatment of diabetic retinopathy.
Focal laser treatment signiﬁ  cantly decreased the risk of 
visual disturbances in diabetic patients with macular edema. 
However, side effects, eg, foveal burns, central visual ﬁ  eld 
defects and retinal ﬁ  brosis, are not uncommon. Pan-retinal 
photocoagulation also has many side effects such as visual 
field constriction, night blindness, and exacerbation of 
macular edema. However, pan-retinal laser photocoagulation 
signiﬁ  cantly decreased the risk of visual disturbances in dia-
betic patients with severe non-proliferative and proliferative 
retinopathy. Early vitrectomy reduced the risk of visual dis-
turbances in diabetic patients with proliferative retinopathy 
and vitreous hemorrhage. Again, there are many side effects 
of vitrectomy including vitreous hemorrhage, retinal detach-
ment, neovascular glaucoma, and infection.
Intravitreal or sub-Tenon injections of triamcinolone 
acetonide (TA) has been recently used to treat the macular 
edema common in diabetic patients, and during the early 
post-TA period, there were improvements in both the macular 
edema and visual acuity (Martidis et al 2002; Avitabile et al 
2005; Sorbin and D'Amico 2005; Jonas et al 2006a). Steroids 
are known to up-regulate the expression of tight junctions 
proteins, eg, occludin and ZO-1, in endothelial cells, and 
this increase reduce the increased vascular permeability in 
the retina (Antonetti et al 2002). Unfortunately, repeated 
injections of TA are frequently required, and there are many 
side effects such as increased intraocular pressure, cataracts, 
and infections (Gillies et al 2004; Jonas et al 2005, 2006b; 
Westfall et al 2005). Although long-term follow-up studies of 
TA must be made, the treatments by TA may be considered 
together with laser treatments and vitrectomy in diabetic 
patients with severe macular edema.
There are many medical therapies that are being tried to 
prevent the development and progression of diabetic retinopa-
thy, eg, aspirin (Early Treatment Diabetic Retinopathy Study 
Research Group 1991b; Chew et al 1995), anti-VEGF agents 
(Cunningham et al 2005; Avery et al 2006; Chun et al 2006; 
Spaide et al 2006), protein kinase C inhibitors (PKC-DRS 
Study Group 2005, 2006; PKC-DMES Study Group 2007), 
growth hormone inhibitors (Kirkegaard et al 1990), and aldose 
reductase inhibitors (Sorbinil Retinopathy Trial Research 
Group 1990). However, Mohamed and colleagues (2007) stated 
that these treatments cannot be recommended for routine use 
because evidence to support their use has not been published.
The most important factor to consider in the management 
and the treatment of diabetic retinopathy is the protection of 
visual function. Because the onset and progression of neu-
ronal and vascular abnomralities lead to visual dysfunction, 
the targets of the therapeutic methods should be the factors 
that are common to both vascular and neuronal abnormalities 
of diabetic retinopathy. Thus, we have stated in an earlier 
review article that two of the candidates common to both 
vascular and neuronal abnormalities in diabetic retinopathy 
are tumor necrosis factor-alpha and Bax (Oshitari 2006). ER 
stress-related factors should also be considered as targets of 
new therapeutic strategies for diabetic retinopathy as well as 
the targets of new therapies for type 2 diabetes because ER 
stress is also related to pancreatic β-cell death and insulin 
resistance in patients with type 2 diabetes.
The results of a recent study showed that oral admin-
istration of chemical chaperones, 4-phenyl butyric acid or 
taurine-conjugated ursodeoxycholic acid, alleviated ER 
stress and improved the action of systemic insulin in diabetic 
animals (Özcan et al 2006). Although the precise mechanism 
involved in the improvement of type 2 diabetes is unclear, 
these chemical chaperones may stabilize protein conforma-
tion and improve the folding capacity of the ER, which in 
turn would reduce the ER stress in these diabetic animals. 
These chemical chaperones may become a standard treatment 
for type 2 diabetes because of their safety proﬁ  les in vivo 
(Maestri et al 1996; Kaplan and Gershwin 2005).Vascular Health and Risk Management 2008:4(1) 120
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Recently, a Bax inhibitor-1 (BI-1) was identiﬁ  ed to be an 
anti-apoptotic protein in mammals (Chae et al 2003), and this 
is relevant because BI-1 can regulate a cell death pathway 
involved in ER stress (Chae et al 2004). In addition, an over-
expression of BI-1 can protect against the neuronal cell death 
induced by ER stress (Dohm et al 2006). Although the mecha-
nism for this protective effect was not determined, a recent 
study showed that BI-1 can inhibit ER stress proteins such as 
CHOP, IRE1α, or phospho-JNK (Lee et al 2007). The activity 
of BI-1 may provide clues on developing new ways to regulate 
the ER stress-induced apoptosis. For example, brain-derived 
neurotrophic factor (BDNF), which is known to reduce the neu-
ronal degeneration of diabetic retinas in vivo (Seki et al 2004), 
prevents ER stress-mediated neuronal cell death by suppressing 
caspase-12 activation in vitro (Shimoke et al 2004).
Although these neuroprotective therapies may be prom-
ising, the prevention of neuronal cell death under chronic 
diabetic stress may have limitations. Even if one major cell 
death pathway is blocked, another cell death pathway may 
become activated. Even when apoptosis can be blocked, 
other types of cell death such as necrosis or autophagy 
may be induced (Koh et al 1995; Hartmann et al 2001; 
Vandenabeele et al 2006). Thus, even if we can establish 
neuroprotective therapies for diabetic retinopathy, the ﬁ  rst 
choice of the treatment for diabetic retinopathy must still be 
the standard treatment of controlling blood glucose levels and 
blood pressure to reduce the causes of diabetic stress.
In conclusion, ER stress is involved in the pathogenesis 
of type 2 diabetes and diabetic retinopathy. The reduction of 
ER stress by chemical chaperones such as 4-phenyl butyric 
acid or taurine-conjugated ursodeoxycholic acid may become 
one of the standard treatments for type 2 diabetes. Such 
treatments may be helpful in preventing the development 
of diabetic retinopathy. Additional studies are required to 
determine the optimal methods to reduce ER stress in patients 
with diabetic retinopathy.
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